2nd Annual IBDHorizons Updates for the Advanced Practice Provider (APP) Symposium

Registration coming soon!

The 2nd Annual IBDHorizons Updates for the Advanced Practice Provider

Is a one-day novel multiplatform event hosted in-person and virtually covering the Pacific Northwest region. This conference will provide IBD focused certified continued education for a target audience of:

  • Advanced nurse practitioners
  • Physician assistant
  • Gastroenterology registered nurses
  • Clinical Nurse Specialists
  • Pharmacists
  • Dieticians
  • Medical assistants
  • Physicians
  • Family practitioners involved in the care of patients with IBD

Attendance and COVID

In-person attendance will be limited to meet the highest safety standards. A full virtual conference platform will be offered exclusively if in-person attendance cannot be safely conducted.

Format

A series of IBD-focused presentations, panel discussions, and case studies with dynamic attendee participation using audience interactive technology.

Presentation Topics

  • Goals of Therapy in IBD: Where are we today?
  • Family Planning, Pregnancy, and IBD Management
  • Novel and Promising Therapeutics in IBD
  • Monitoring Disease Activity: Why & How
  • Infection Risk in IBD: Focus on COVID-19
  • Skin Manifestations of IBD and IBD-therapy
  • Approach to the Symptomatic IBD Patient in Endoscopic
  • Clinical Models of IBD Care: Eye on Telemedicine

 

LEARNING OBJECTIVES

After completion of this activity, participants will be able to:

  1. Outlines the goals of IBD care and Incorporate the latest concepts including treat-to-target in IBD clinical practice to maximize patient outcomes. 
  2. Appraise the available non-invasive testing (including blood, stool tests, and imaging modalities) to evaluate for disease activity in IBD and interpret these studies relative to other objective markers of disease such as endoscopy. 
  3. Assess our current knowledge on infection risk in IBD including COVID-19 and the implications on managing IBD patients especially during the current pandemic, including the risk of complications, interrupting therapy, and vaccination guidelines. 
  4. Review the common dermatologic extraintestinal manifestations in IBD (related to disease, therapy, or complications) and apply a practical approach to screen and intervene as needed.
  5. Review the causes of active symptoms in IBD patients who are in clinical remission and apply a practical approach to diagnose and manage GI symptoms in the absence of active inflammation.
  6. Appraise the available telemedicine models of health care delivery with their advantages and limitations and apply this knowledge to enhance equitable IBD patient care access and outcomes especially for underserved populations.
  7. Recognize the particular challenges related to fertility, pregnancy, prenatal and postnatal care in IBD and review the latest recommendations. 
  8. Discuss the newly approved and soon-to-be approved biologic and non-biologic therapies for IBD, including the risks, efficacy, and special considerations when utilizing these therapies.

  • 00

    days

  • 00

    hours

  • 00

    minutes

  • 00

    seconds

Hourly Schedule

New Day

8:15 - 9:00
Goals of Therapy in IBD: Where are we today?
Speakers:
Ghassan Wahbeh
9:00 - 9:45
Family Planning, Pregnancy, and IBD Management
Speakers:
Sarah Chou
9:45 - 10:15
Break
10:15 - 11:00
Novel and Promising Therapeutics in IBD
Speakers:
Scott D. Lee
11:00 - 11:45
Monitoring Disease Activity: Why & How
Speakers:
Namita Singh
11:45 - 12:15
Lunch
12:15 - 13:00
Infection Risk in IBD: Focus on COVID-19
Speakers:
Jeff Jacobs
13:00 - 13:45
Skin Manifestations of IBD and IBD-therapy
Speakers:
Anita Afzali
13:45 - 14:30
Approach to the Symptomatic IBD Patient in Endoscopic
Speakers:
David Suskind
14:30 - 15:15
Clinical Models of IBD Care: Eye on Telemedicine
Speakers:
Mitra Barahimi
Ghassan Wahbeh
Ghassan Wahbeh
MD, Director of the Inflammatory Bowel Disease Center at Seattle Children’s Hospital
Ghassan Wahbeh, MD, is the director of the Inflammatory Bowel Disease Center at Seattle Children’s Hospital. He is professor of pediatrics and gastroenterology at the University of Washington School of Medicine. Dr. Wahbeh’s clinical focus is in advanced care for children adolescents and young adultswith Crohn’s Disease and Ulcerative Colitis, including advanced therapeutics and pre and post-surgery IBD management. Dr. Wahbeh’s research interests include advanced management of moderate and severe colitis in the outpatient and inpatient setting, managing complicated Crohn’s disease including fistulizing and stricturing phenotypes, mucosal healing in IBD, navigating surgical options in IBD and novel therapies.
 Dr. Wahbeh is actively involved as teaching faculty in medical student education, resident training and fellow physician specialty training. He is the honored recipient of the Outstanding Teaching Faculty Award, as well as the Family Choice Award, and the Northwest Crohns & Colitis Foundation service award. He continues to serve as a member of the National Professional Education Committee and the Northwest Medical Advisory Committee of the Crohns and Colitis Foundation of America.
Sarah Chou
Scott D. Lee
Scott D. Lee
MD, Associate Professor of Medicine
Dr. Lee is an associate professor of medicine with expertise in inflammatory bowel disease (Crohn’s disease and ulcerative colitis). Dr. Lee earned his bachelor’s degree at Pomona College and his M.D. at Jefferson Medical College. He completed his residency in internal medicine at the University of Colorado in Denver. After residency, Dr. Lee completed his gastroenterology fellowship at the University of Washington. After completing his fellowship, he attended the University of Chicago and Cedar-Sinai in Los Angeles as a visiting physician to gain additional training in IBD. Since finishing his fellowship, he has been an attending gastroenterology physician at the University of Washington Medical Center. Currently his clinical practice is at the Digestive Disease Center at the University of Washington and is dedicated exclusively to providing care to patients with the diagnosis of IBD. His research is focused on inflammatory bowel diseases (IBD) including – new therapies for IBD, improving outcomes in the treatment and long term management of IBD, evaluation of non-invasive biomarkers to assess disease activity in IBD patients and the effects of the microbiome on IBD. He has participated in more than 100 clinical trials in IBD and continues to have an active clinical research program. He is a member of the Crohn’s Colitis Foundation of America (CCFA), American Gastroenterology Association, American College of Gastroenterology and American Society of Gastrointestinal Endoscopy. He is a past chair of Northwest CCFA Chapter Medical Advisory Committee (CMAC) and continues as a current member of the CMAC.
Namita Singh
Jeff Jacobs
Anita Afzali
Anita Afzali
MD, MPH, Associate Professor of Clinical Medicine, Gastroenterologist
Dr. Anita Afzali is an Associate Professor of Clinical Medicine and a Gastroenterologist that specializes in Inflammatory Bowel Disease (IBD) at The Ohio State University Wexner Medical Center. She is the Director of Operations for the Division of Gastroenterology, Hepatology and Nutrition, as well as the Medical Director of the OSU Inflammatory Bowel Disease Center. She holds the Abercrombie & Fitch Endowed Chair in Inflammatory Bowel Disease. She received her medical degree and then completed Internal Medicine residency and Gastroenterology fellowship at the University of Washington in Seattle, WA. While in fellowship, Dr. Afzali worked in outcomes research and epidemiology, and also graduated with a Master’s in Public Health. Her sub-specialty training includes a one-year advanced IBD fellowship at the University of Washington, prior to becoming faculty. While practicing at the University of Washington – Harborview Medical Center, Dr. Afzali served as the Director of the IBD Program and Associate Medical Director of Gastroenterology Clinics. Her research interests include clinical outcomes and association of bowel and joint disease, influence of the metabolic syndrome and impact of race/ethnicity in IBD, as well as pharmacoeconomics, pediatric-to-adult transition, and women of childbearing age with IBD. She is also extensively involved in IBD clinical trials for investigational therapies. She has extensive peer-reviewed publications, an invited lecturer on national and international programs, and serves on several international advisory boards and committees including Co-Chair of the Crohn’s & Colitis National Professional Education Committee and Member of the ACG Minority Affairs and Cultural Diversity committee.
David Suskind
Mitra Barahimi
Mitra Barahimi
Assistant Professor of Medicine
Dr. Barahimi is an assistant professor of medicine at the University of Washington with expertise in inflammatory bowel disease. She earned her bachelor’s degree and MD at the University of Washington. She went on to complete her residency in internal medicine and fellowship in gastroenterology at the University of Washington. In her clinical practice, she exclusively cares for patients with Crohn’s disease and ulcerative colitis. She is the principal investigator of IBD QORUS, a national quality improvement project that aims to improve the quality of care for patients with inflammatory bowel disease. She is also involved in clinical trials for new investigational therapies for inflammatory bowel disease. She is a member of the Crohn’s Colitis Foundation of America (CCFA), American Gastroenterology Association, American College of Gastroenterology and American Society of Gastrointestinal Endoscopy.

Date

Oct 16 2021

Time

8:00 am - 3:30 pm

Location

TBD
QR Code

Leave a Reply

Your email address will not be published. Required fields are marked *